Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -38.51% is 30% above its 5-year average of -54.83%, near the high end of its 5-year range (-128.72%–-34.84%).
As of the fiscal period ended Tuesday, June 30, 2026. 47.89% above its 12-month average of -73.90%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -38.51%.
RETURN ON EQUITY (ROE)
-38.51%
RETURN ON EQUITY (ROE) AVG TTM
-73.90%
RETURN ON EQUITY (ROE) AVG 3Y
-67.28%
RETURN ON EQUITY (ROE) AVG 5Y
-54.83%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+47.89%
CURRENT VS 3Y AVG
+42.76%
CURRENT VS 5Y AVG
+29.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 653 covered companies
CURRENT VS SECTOR MEDIAN
+4.20%
vs the sector median at left
Definium Therapeutics, Inc.
Market Cap
$4.70B
Return on Equity (ROE)
-38.51%
TTM Avg
-73.90%
3Y Avg
-67.28%
5Y Avg
-54.83%
Market Cap
$4.69B
Return on Equity (ROE)
3.43%
TTM Avg
-1.67%
3Y Avg
-7.64%
5Y Avg
-9.04%
Market Cap
$4.65B
Return on Equity (ROE)
16.63%
TTM Avg
15.37%
3Y Avg
15.09%
5Y Avg
11.91%
Market Cap
$4.82B
Return on Equity (ROE)
-2.55%
TTM Avg
-28.50%
3Y Avg
-30.36%
5Y Avg
-30.19%
Market Cap
$4.56B
Return on Equity (ROE)
6.24%
TTM Avg
-11.62%
3Y Avg
-98.18%
5Y Avg
-98.18%
Market Cap
$4.84B
Return on Equity (ROE)
-11.92%
TTM Avg
-22.12%
3Y Avg
-20.62%
5Y Avg
-23.54%
Market Cap
$4.86B
Return on Equity (ROE)
N/A
TTM Avg
-23.20%
3Y Avg
-51.91%
5Y Avg
-56.25%
Market Cap
$4.42B
Return on Equity (ROE)
N/A
TTM Avg
-107.43%
3Y Avg
-58.28%
5Y Avg
-52.10%
Market Cap
$4.39B
Return on Equity (ROE)
-44.68%
TTM Avg
-52.94%
3Y Avg
-55.51%
5Y Avg
-46.01%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Definium Therapeutics, Inc. (DFTX) | $4.70B | -38.51% | -73.90% | -67.28% | -54.83% |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 3.43% | -1.67% | -7.64% | -9.04% |
| Option Care Health, Inc. (OPCH)vs › | $4.65B | 16.63% | 15.37% | 15.09% | 11.91% |
| Dianthus Therapeutics, Inc. (DNTH)vs › | $4.82B | -2.55% | -28.50% | -30.36% | -30.19% |
| BillionToOne, Inc. (BLLN)vs › | $4.56B | 6.24% | -11.62% | -98.18% | -98.18% |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.84B | -11.92% | -22.12% | -20.62% | -23.54% |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.86B | N/A | -23.20% | -51.91% | -56.25% |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.42B | N/A | -107.43% | -58.28% | -52.10% |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.39B | -44.68% | -52.94% | -55.51% | -46.01% |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.37B | -42.32% | -13.82% | -5.11% | -5.11% |
ROE
-38.5%
ROA
-31.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -38.51% |
| 2026-03-31 | -85.19% |
| 2025-12-31 | -55.30% |
| 2025-09-30 | -128.72% |
| 2025-06-30 | -61.77% |
| 2025-03-31 | -34.84% |
| 2024-12-31 | -45.01% |
| 2024-09-30 | -37.30% |
| 2024-06-30 | -50.50% |
| 2024-03-31 | -63.92% |
| 2023-12-31 | -122.52% |
| 2023-09-30 | -79.99% |
| 2023-06-30 | -71.09% |
| 2023-03-31 | -48.46% |
| 2022-12-31 | -37.63% |
| 2022-09-30 | -44.74% |
| 2022-06-30 | -55.77% |
| 2022-03-31 | -71.44% |
| 2021-12-31 | -61.34% |
| 2021-09-30 | -53.43% |
| 2021-06-30 | -45.46% |
| 2021-03-31 | -21.68% |
| 2020-12-31 | -44.73% |
| 2019-08-31 | -40.78% |
| 2019-05-31 | -19.89% |
| 2019-02-28 | -27.83% |
| 2018-11-30 | -31.11% |
| 2018-08-31 | -31.09% |
| 2018-05-31 | -42.85% |
| 2018-02-28 | -38.29% |
| 2017-11-30 | -37.20% |
| 2017-08-31 | -42.59% |
